– France becomes Seegene’s ninth commercial subsidiary abroad and the third in Europe, after Italy and Germany.
– The country ranks second in the European molecular diagnostics market, driven by demand for sexually transmitted infections, gastrointestinal tests and respiratory virus detection.
– The new subsidiary is expected to accelerate the wider adoption of Seegene’s developing solutions, CURECA™ and STagora™, in Europe
SEOUL, South Korea, December 5, 2025 /PRNewswire/ — Seegene, Inc., a global leader in molecular diagnostics (MDx), today announced the creation of a new subsidiary in France to strengthen its European presence and support global sales expansion.
The new subsidiary will strengthen local engagement with customers and partners through enhanced technical support, market development and collaboration with healthcare stakeholders.
According to the international market research firm Grand View Research, Inc., the French MDx market is estimated at around 600 million euros, or around 15% of the European total. It is the second largest market in the region after Germany, which has a market share of 19 percent. In France, demand is particularly strong for diagnostic tests targeting sexually transmitted infections (STIs), gastrointestinal (GI) tract infections and respiratory infections. Through its subsidiary, Seegene aims to increase sales of these product lines while introducing a broader portfolio including cervical cancer and other multiplex diagnostic categories.
“In the French market, divided between the private and public sectors, the ability to quickly deliver innovative products and meet the efficiency needs of laboratories is a key competitive factor,” said Daniel Shin, executive vice president and global head of sales and marketing at Seegene. “The subsidiary will enable Seegene to better understand the French healthcare landscape, strengthen local customer service and accelerate the growth of the company’s in vitro diagnostics business through dedicated local expertise.
The subsidiary also constitutes a strategic position for the European deployment of Seegene’s solutions under development, CURECA™, a fully automated unmanned PCR system, and STAgora™, a real-time diagnostic data analysis and predictive information platform.
The addition of France brings Seegene’s overseas sales subsidiaries to nine, completing its global distribution network of 90 distributors in 94 countries.
In the first half of 2025, overseas sales accounted for approximately 93% of Seegene’s total revenue, with Europe accounting for 63%. The region remains a key growth engine for the company’s global expansion roadmap.
Disclaimer
CURECA™ and STAgora™ are under development and are not available for diagnostic use.
About Seegene
Seegene has over 25 years of dedicated experience in R&D, manufacturing and business related to real-time syndromic PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic, when Seegene provided more than 340 million COVID-19 tests to more than 100 countries around the world. The key feature of Seegene’s real-time syndromic PCR technology is the ability to simultaneously test 14 pathogens causing similar signs and symptoms in a single tube with quantitative information.
Visit: Seegene.com and follow linkedin.com/company/seegene-inc
SOURCE Seegene Inc.
